{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:17:23Z","timestamp":1788023843172,"version":"build-2784847793"},"reference-count":72,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2024,2,1]]},"DOI":"10.1080\/03007995.2023.2288280","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T05:11:51Z","timestamp":1700802711000},"page":"155-163","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of tyrosine-kinase-2 and phosphodiesterase-4 inhibitors for scalp psoriasis: a systematic review and meta-analysis"],"prefix":"10.1080","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8900-7281","authenticated-orcid":false,"given":"Sotirios G.","family":"Tsiogkas","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly","place":["Larissa, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3539-2035","authenticated-orcid":false,"given":"Eleni K.","family":"Karamitrou","sequence":"additional","affiliation":[{"name":"Primary Health Center of Mouzaki","place":["Karditsa, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4167-6595","authenticated-orcid":false,"given":"Maria G.","family":"Grammatikopoulou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly","place":["Larissa, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-7292","authenticated-orcid":false,"given":"Efterpi","family":"Zafiriou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly","place":["Larissa, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-7902","authenticated-orcid":false,"given":"Dimitrios P.","family":"Bogdanos","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly","place":["Larissa, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02469-2"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.2871"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.890"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-020-00099-7"},{"key":"e_1_3_5_7_1","article-title":"Manifestations and management of difficult-to-treat psoriasis","volume":"10","author":"Aldredge LM","year":"2018","unstructured":"Aldredge LM, Higham RC. Manifestations and management of difficult-to-treat psoriasis. J Dermatol Nurses Assoc. 2018;10:189\u2013197. Available from: https:\/\/journals.lww.com\/jdnaonline\/fulltext\/2018\/07000\/manifestations_and_management_of.2.aspx","journal-title":"J Dermatol Nurses Assoc"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00521-z"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1448788"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00409-4"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2173170"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2173171"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00986-0"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13508"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01796-y"},{"key":"e_1_3_5_16_1","first-page":"105","article-title":"Otezla (Apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis","volume":"8","author":"Fala L.","year":"2015","unstructured":"Fala L. Otezla (Apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Heal Drug Benefits. 2015;8:105\u2013110.","journal-title":"Am Heal Drug Benefits"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.01.001"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2014.05.014"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231153863"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_5_26_1","first-page":"221","article-title":"Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL","volume":"17","author":"Stein Gold L","year":"2018","unstructured":"Stein Gold L, Bagel J, Lebwohl M, et\u00a0al. Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL. J Drugs Dermatol. 2018;17:221\u2013228.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14015"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60642-4"},{"key":"e_1_3_5_29_1","first-page":"66","article-title":"Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast: subset analysis of patients with scalp psoriasis in the phase 3 POETYK PSO-1 and PSO-2 trials","volume":"63","author":"Foley P.","year":"2022","unstructured":"Foley P. Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast: subset analysis of patients with scalp psoriasis in the phase 3 POETYK PSO-1 and PSO-2 trials. Australas J Dermatol. 2022;63:66.","journal-title":"Australas J Dermatol"},{"issue":"1","key":"e_1_3_5_30_1","first-page":"65S","article-title":"Efficacy and safety of apremilast in patients with mild to moderate psoriasis: results from the 16-week, double-blind phase of the ADVANCE trial","volume":"25","author":"Gold LS","year":"2021","unstructured":"Gold LS, Papp K, Leonardi C, et\u00a0al. Efficacy and safety of apremilast in patients with mild to moderate psoriasis: results from the 16-week, double-blind phase of the ADVANCE trial. J Cutan Med Surg. 2021;25(1 SUPPL):65S\u201366S.","journal-title":"J Cutan Med Surg"},{"key":"e_1_3_5_31_1","unstructured":"NCT03611751. An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate-to-severe plaque psoriasis (POETYK-PSO-2). Clinicaltrials.gov. 2018."},{"key":"e_1_3_5_32_1","unstructured":"NCT03624127. Effectiveness and safety of BMS-986165 compared to placebo and active comparator in participants with psoriasis (POETYK-PSO-1). Clinicaltrials.gov. 2018."},{"key":"e_1_3_5_33_1","unstructured":"NCT03721172. Apremilast as a direct treatment for mild-to-moderate plaque psoriasis versus placebo: an analysis of clinical safety and efficacy (ADVANCE). Clinicaltrials.gov. 2018."},{"key":"e_1_3_5_34_1","first-page":"67","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor: improvements in nail and scalp psoriasis and psoriasis area and severity index in patients with moderate to severe plaque psoriasis","author":"Papp K","year":"2015","unstructured":"Papp K, Crowley J, Paul C, et\u00a0al. Apremilast, an oral phosphodiesterase 4 inhibitor: improvements in nail and scalp psoriasis and psoriasis area and severity index in patients with moderate to severe plaque psoriasis. Arthritis Rheumatol. 2015;67 (Supplement 10):Meeting Abstract 2889.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.1113"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.11.780"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.276"},{"key":"e_1_3_5_38_1","first-page":"AB164","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2)","volume":"70","author":"Paul C","year":"2014","unstructured":"Paul C, Crowley J, Cather J, et\u00a0al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2). J Am Acad Dermatol. 2014;70:AB164. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0190962214006847","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_5_39_1","first-page":"2113","article-title":"Efficacy and safety of apremilast and switch from etanercept in patients with moderate to severe psoriasis: 52-week results","volume":"68","author":"Reich K","year":"2016","unstructured":"Reich K, Soung J, Gooderham M, et\u00a0al. Efficacy and safety of apremilast and switch from etanercept in patients with moderate to severe psoriasis: 52-week results. Arthritis Rheumatol. 2016;68:2113\u20132114.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.1732"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.10.041"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.001"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.040"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.440"},{"key":"e_1_3_5_45_1","first-page":"25","article-title":"Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast: subset analysis of patients with scalp psoriasis in the phase 3 POETYK PSO-1 and POETYK PSO-2 trials","volume":"20","author":"Thaci D","year":"2022","unstructured":"Thaci D, Rich P, Sofen H, et\u00a0al. Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast: subset analysis of patients with scalp psoriasis in the phase 3 POETYK PSO-1 and POETYK PSO-2 trials. J Dtsch Dermatol Ges. 2022;20\u2009MA-P:25.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"e_1_3_5_46_1","first-page":"S21","article-title":"Efficacy and safety of apremilast in patients with moderateto-severe plaque psoriasis of the scalp: results of a phase III, multicenter, randomized, placebocontrolled, double-blind study","volume":"12","author":"Van Voorhees A","year":"2019","unstructured":"Van Voorhees A, Stein Gold L, Lebwohl M, et\u00a0al. Efficacy and safety of apremilast in patients with moderateto-severe plaque psoriasis of the scalp: results of a phase III, multicenter, randomized, placebocontrolled, double-blind study. J Clin Aesthet Dermatol. 2019;12(5):S21.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.072"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.277"},{"key":"e_1_3_5_49_1","unstructured":"JPRN-JapicCTI-184213. A multi-center randomized double-blind placebo- and active comparator-controlled phase 3 study to evaluate the efficacy and safety of BMS-986165 in subjects with moderate-to-severe plaque psoriasis. 2016."},{"issue":"5","key":"e_1_3_5_50_1","first-page":"S15","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis: pooled 16-week efficacy in patient subgroups (ESTEEM 1 and 2)","volume":"9","author":"Korman NJ","year":"2016","unstructured":"Korman NJ, Poulin Y, Griffiths CEM, et\u00a0al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis: pooled 16-week efficacy in patient subgroups (ESTEEM 1 and 2). J Clin Aesthet Dermatol. 2016;9(5):S15\u2013S16.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_5_51_1","unstructured":"NCT01194219. Study to evaluate safety and effectiveness of oral apremilast (CC-10004) in patients with moderate to severe plaque psoriasis (ESTEEM 1). Clinicaltrials.gov. 2010."},{"key":"e_1_3_5_52_1","unstructured":"NCT01232283. Study to evaluate safety and effectiveness of oral apremilast (CC-10004) in patients with moderate to severe plaque psoriasis (ESTEEM 2). Clinicaltrials.gov. 2010."},{"key":"e_1_3_5_53_1","unstructured":"NCT01690299. Phase 3b safety and efficacy study of apremilast to treat moderate to severe plaque-plaque psoriasis. Clinicaltrials.gov. 2012."},{"key":"e_1_3_5_54_1","unstructured":"NCT02425826. A phase 4 study of efficacy and safety of apremilast in subjects with moderate plaque psoriasis (UNVEIL). Clinicaltrials.gov. 2015."},{"key":"e_1_3_5_55_1","unstructured":"NCT03123471. A study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp (STYLE). Clinicaltrials.gov. 2017."},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00747-5"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00658-x"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.07.169"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17392"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18166"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14832"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15293"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406223231152785"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42519"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad098"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.059"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1770175"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1770167"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2113872"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes12091398"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.6.supp.41"},{"key":"e_1_3_5_72_1","unstructured":"NCT04167462. An investigational study to evaluate experimental medication BMS-986165 compared to placebo in participants with plaque psoriasis (POETYK-PSO-3) in mainland China Taiwan and South Korea (POETYK-PSO-3). 2019."},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.03.640"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2023.2288280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:38:34Z","timestamp":1775047114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2023.2288280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"alternative-id":["10.1080\/03007995.2023.2288280"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2023.2288280","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}